Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety,
tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2
dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Age: 18 years - 66+
Gender: All
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and
efficacy of AI-081 in solid tumors.
Age: 18 years - 66+
Gender: All
Lamivudine for Solid Tumors
Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors.
Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai
Health System.
Primary Objective:
For Phase 1b to determine the safety and tolerabilit...
Age: 18 years - 66+
Gender: All
Study of SGR-3515 In Participants With Advanced Solid Tumors.
The purpose of this study is to learn about the effects of a new study drug, called
SGR-3515 that may be a treatment for advanced solid tumors.
Age: 18 years - 66+
Gender: All
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of
cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are
looking for ways to stop the actions of abnormal proteins made from the mutated KRAS
gene. The so-c...
Age: 18 years - 66+
Gender: All
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD)
in the following tumor types: endometrial cancer (EC); head and neck squamous cell
carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC);
hepatocel...
Age: 18 years - 66+
Gender: All
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug
XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for
further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Age: 15 years - 66+
Gender: All
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor
activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy
following chemotherapy in participants with advanced human epidermal growth factor
receptor 2 (...
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase I, open-label, dose-escalation and expansion study
designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity,
pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and
in combination w...
Age: 18 years - 66+
Gender: All
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion
study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in
participants with advanced solid tumors. The main purpose of this study is to explore the
recomm...
Age: 18 years - 66+
Gender: All
A Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
The goal of this clinical trial is to study the safety and tolerability in all advanced
solid tumors, including advanced urothelial carcinoma.
The main question[s] it aims to answer are:
- Is FX-909 safe and tolerable
- What is the right dose level for patie...
Age: 18 years - 66+
Gender: All
A Study of ASP1002 in Adults for Treatment of Solid Tumors
The main aims of this study are:
- To check the safety of ASP1002 in people with certain solid tumors.
- To check if the people can tolerate ASP1002.
- To find a suitable dose of ASP1002. This study will be in 2 parts. In Part 1,
different small groups of ...
Age: 18 years - 66+
Gender: All
Study of DF9001 in Patients With Advanced Solid Tumors
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell
activation signals to specific receptors on cancer cells. The study will occur in two phases.
The first phase will be a dose escalation phase, enrolling patients with various t...
Age: 18 years - 66+
Gender: All
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of
JZP815 in participants with advanced or metastatic solid tumors harboring alterations in
the MAPK pathway.
Age: 18 years - 66+
Gender: All
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advanced solid tumor malignancies
and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- casdatifan monothe...
Age: 18 years - 66+
Gender: All
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
Age: 18 years - 66+
Gender: All
A Study of YL201 in Patients with Advanced Solid Tumors
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201
conducted in China and the United States. The study will include 2 parts: a dose
escalation part (Part 1) followed by a dose expansion part (Part 2).
Part 1 will estimate the M...
Age: 18 years - 66+
Gender: All
A Study of XMT-1660 in Participants With Solid Tumors
A Study of XMT-1660 in Solid Tumors
Age: 18 years - 66+
Gender: All
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RBS2418 (investigational product) is a specific immune modulator, working through
ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to
anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine
monophosphate-adenosine monophosphate...
Age: 18 years - 66+
Gender: All
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of
IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with
advanced solid tumors
Age: 18 years - 66+
Gender: All